0.795
0.06 (7.43%)
| Penutupan Terdahulu | 0.740 |
| Buka | 0.740 |
| Jumlah Dagangan | 1,528,382 |
| Purata Dagangan (3B) | 2,477,813 |
| Modal Pasaran | 978,716,608 |
| Harga / Pendapatan (P/E Ke hadapan) | 6.75 |
| Harga / Jualan (P/S) | 2,554.14 |
| Harga / Buku (P/B) | 4.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -164,535.56% |
| EPS Cair (TTM) | -0.530 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -68.30% |
| Nisbah Semasa (MRQ) | 2.94 |
| Aliran Tunai Operasi (OCF TTM) | -161.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -94.87 M |
| Pulangan Atas Aset (ROA TTM) | -83.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -3,383.08% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | OPTHEA FPO [OPT] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.38 |
|
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.22% |
| % Dimiliki oleh Institusi | 41.82% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |